Entity

Time filter

Source Type

San Diego, CA, United States

Patent
HemaQuest Pharmaceuticals and Boston University | Date: 2011-03-11

Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.


Patent
HemaQuest Pharmaceuticals and Boston University | Date: 2015-06-02

Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.


Patent
Boston University and HemaQuest Pharmaceuticals | Date: 2010-12-08

Disclosed herein are methods and low dose regimens for increasing fetal hemoglobin levels in patients with red blood cell disorders, such as beta thalassemia, sickle cell disease, other anemias, or blood loss. Fetal and total hemoglobin levels and red blood cell counts are increased by administering 2,2-dimethylbutyrate (DMB) alone or in combination with hydroxyurea, decitabine or an HDAC inhibitor. Treatment can be continued for at least two weeks.


News Article | December 6, 2010
Site: www.xconomy.com

After hiring former Favrille CEO John Longenecker a few weeks ago, HemaQuest Pharmaceuticals said Friday it is relocating its headquarters to San Diego. The three-year-old startup, which is developing drugs to treat hemoglobin-associated diseases, plans to maintain an office in Seattle, but the center of gravity is now here. In its statement, HemaQuest also says Dr. Richard Ghalie is joining HemaQuest as chief medical officer and Tamara Seymour will serve as the company’s new chief financial officer. Ghalie and Seymour both worked previously at San Diego-based Favrille with Longenecker, who said he was pleased to be reunited with his former colleagues. Favrille was a public company focused on developing a drug that was intended to trigger the immune system to fight non-Hodgkins lymphoma. The drug failed to show any benefit in a late-stage clinical trial in 2008. MyMedicalRecords.com acquired Favrille in a reverse merger transaction in early 2009. “I look forward to an aggressive clinical program for our lead product, HQK-1001, an orally administered Small Chain Fatty Acid Derivative (SCFAD), as a potential new treatment for hematologic disorders such as sickle cell disease and beta thalassemia,” Longenecker said in the statement. The drug candidate has orphan drug status in both the United States and Europe. The company says SCFADs represent a new class of drugs with the potential to stimulate the expression of specific target genes to treat serious and life-threatening genetic blood disorders and malignant hematologic diseases. The move to San Diego also brings HemaQuest within the orbit of Forward Ventures, the San Diego venture firm that was among its early investors. Latterell Venture Partners, DeNovo Ventures, and Lilly Ventures are also backers, according to Seattle’s TechFlash. HemaQuest has raised at least $36 million since it was founded in 2007 by scientists at Boston University, Colorado State University, and the University of Washington, including Susan Perrine, Douglas Faller, Ronald Berenson, Thalia Papayannopoulou and George Stamatoyannopoulos. Berenson, who was previously CEO, and Perrine, the former chief scientific officer and vice president of clinical affairs, will continue as consultants to the company.


News Article | March 12, 2012
Site: www.xconomy.com

HemaQuest Gets $13M Transfusion in Extension of Series B Financing San Diego-based HemaQuest Pharmaceuticals, a biotech developing small molecule drugs for treating sickle cell disease and other blood disorders, has gotten another capital transfusion after once again extending its Series B financing. In a statement today, HemaQuest says it has raised an additional $13 million to support a mid-stage trial of the company’s lead drug candidate for patients with sickle cell disease. That’s almost equal to the $16 million HemaQuest previously raised in three separate steps of its Series B financing. The participating investors are Aberdare Ventures, De Novo Ventures, Forward Ventures, Latterell Venture Partners, and Lilly Ventures. HemaQuest was founded in Seattle in 2007, and moved its headquarters to San Diego in late 2010 after hiring former Favrille CEO John Longenecker. HemaQuest says its most recent extension should enable the company to complete a planned Phase 2b trial of its lead drug candidate by early 2014. The experimental drug, HQK-1001, belongs to a class of compounds known as Short Chain Fatty Acid Derivatives (SCFADs) that have been shown to stimulate fetal hemoglobin expression and red blood cell production in the laboratory.

Discover hidden collaborations